Commercial Strategy & Market Access

Growth through innovation is often a top priority, but ensuring that the process delivers competitive advantage is challenging. The demands of value-based healthcare put even more pressure on innovation as stakeholders demand increased quality while controlling costs. Meeting this challenge requires identifying real clinical and economic unmet needs and the types of evidence that will be required to support adoption and reimbursement. We focus on value assessment and creation that helps companies achieve sustained competitive advantage.

It is one thing to identify a market opportunity, but still another to execute and win in today’s value-conscious marketplace. We firmly embed our product development and market access expertise into market opportunity assessment and forecasting. We understand how payer acceptance, health economic value, and evidence investment requirements are the building blocks to build robust business cases. Our proprietary analytics regarding technology development, evidence timing and impact, and reimbursement risk enable us to deliver real-world insights that inform actionable market and growth strategies.

Payers and health systems are seeking value and demanding more from novel drugs, devices, and diagnostic technologies than ever before. We have a deep understanding of the global payer landscape and go beyond policy makers to understand financial risk at the hospital or health system level better align the value our clients deliver with the expectations of reimbursement and funding stakeholders. Our rigorous understanding of the clinical and economic burden of disease allows us to build strategic reimbursement road maps that address everything from coding to policy, pricing, and evidence development.

Payers, clinicians, regulators, and investors are increasingly assessing the value of innovation in terms of results — both clinical and economic. We develop robust health economic analysis and value communication tools that deliver success in an environment where proving clinical and economic value to payers and providers is essential for success. We proactively and seamlessly work with clients to anticipate the market needs and uses of study results so they can develop and capitalize on a comprehensive and integrated research value communication approach.

Today’s medical technology M&A environment is extremely competitive and innovators must move quickly to identify opportunities, evaluate them, and close transactions that will drive real growth. We help innovators anticipate market evolution to create sustained value and achieve an edge over the competition. Our expertise is built on the realities of payer coverage and pricing in a value-based healthcare environment and identifies and prioritizes opportunities and delineates evidence gaps and reimbursement challenges, offering you a much clearer picture of transaction opportunities and risks.

As our understanding of the genotypic and phenotypic basis of disease grows through advanced diagnostics, big data, and connectivity, delivering the right treatment to the right patient at the right time depends on a complex mix of analytics and insights. From in vitro diagnostics to imaging and digital tools, activating precision medicine also means delivering the right insights to the right stakeholders at the right time. Broad and timely clinician patient access to innovative diagnostic technologies and informatics tools that guide clinical decision-making in an evolving precision medicine landscape has emerged as a prerequisite for the successful implementation of precision medicine. Our capabilities in global market access, commercial strategy, data and advanced analytics, and partnering puts us in a unique position to support medicine innovators in developing effective commercialization strategies and globally scalable solutions needed to drive routine patient access to appropriate diagnostic technologies and resulting intervention.